



The Fourth MedTech Investing Europe Conference

Featuring med tech company investment opportunity presentations & investor/innovator one-to-one meetings

15th & 16th February 2007
Ecole Polytechnique Fédérale de Lausanne, Switzerland

Bringing together investors and innovators in an exclusive and focused educational and networking environment.

To book online please visit our website
www.medtechinvesting.com

In partnership with:



In official association with:



Sponsored by:



Organised by:



Media partner:



MED · TECH
BUSINESS REVIEW

WHO SHOULD ATTEND?

Our previous MedTech Investing Europe conference was attended by over 200 delegates from 16 countries representing leading investors and major healthcare corporations.

To ensure an exclusive and focused audience, attendance from paying delegates is restricted to investors and strategic partners, specifically:

- Institutional investors: pension funds, foundations, insurance companies
- Corporate investors and strategic partners: investment and partnering divisions of major healthcare corporations
- Investment fund managers: equity fund managers, hedge fund managers, investment analysts, private equity & venture capital fund managers
- Family offices and private investment companies
- Private investors

The only attendees from outside these groups permitted at the conference are the med tech presenting companies, speakers and small delegations from our sponsors.

QUOTES FROM DELEGATES AT PREVIOUS MTI CONFERENCES:

"This conference has developed into an unmissable fixture in the calendar of those who want to access cutting-edge investment opportunities, original thinking, and incisive market analyses in med tech"

MAURICE WAGNER
DIRECTOR GENERAL, EUCOMED, BELGIUM

"Exposure at MedTech Investing Europe brought HeartSmart good reviews, great contacts and currently funding is being considered from three serious interested investors. If you are looking for investors this is the place to show off your product"

DR KENNETH WARRING-DAVIES
DIRECTOR, HEARTSMART, UK

"I made some excellent contacts at MTI Europe which led to some serious interest in Bioring's product from investors. I would highly recommend this conference as an important forum in connecting med tech companies with the investment community"

RAYMOND ANDRIEU
CHAIRMAN AND CEO, BIORING SA, SWITZERLAND

"We were delighted with the interest shown in our product as a direct result of the presentation. Thereafter, we made some interesting contacts at the conference which we have since followed up on. One of them has led to ongoing in-depth promising discussions."

CHRISTIAN STUERZINGER
CEO, CARDIOLA LTD, SWITZERLAND

CONFERENCE ORGANISED IN CONJUNCTION WITH ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE

The conference takes place at the Ecole Polytechnique Fédérale de Lausanne (EPFL). EPFL is ranked among Europe's premier higher education institutions for technological and scientific innovation.



The science park on EPFL's site is also home to more than 100 start-up technology enterprises and numerous investors. Stimulating and strengthening the link between the lab and business is key to EPFL's philosophy.

IMPERIAL COLLEGE LONDON

Imperial College London, founded in 1907, is one of the world's leading universities and is among Europe's premier institutions for research and market-led innovation with a clear focus on science technology and medicine.



Through their technology commercialisation company, Imperial are a European leader in spinning out new business ideas developed on campus. Over 60 spin out companies have been created and £175 million has been attracted in external investment.

ABOUT THE ORGANISERS

The MedTech Investing Europe conference is organised by Campden Publishing Ltd, an independent information provider founded in 1987.



The company operates in the international private wealth management and European healthcare industries.

In healthcare, Campden publishes information for European hospitals working with groups such as HOPE/The Standing Committee of Hospitals of the European Union, for whom it organised the 2001 European Hospital Healthcare Congress. In the UK Campden provides information for practice nurses and members of the Royal College of General Practitioners.

In private wealth management, as well as publishing, Campden organises private conferences for a community of ultra high net worth private investors and their related private entities.

MEDIA PARTNER

MedTech Business Review is a major new information resource for everyone concerned with the medical technology industry in Europe and around the world. The pharmaceuticals sector has a wealth of media surrounding it, feeding vital information to industry professionals, investors and the vast healthcare market; the fast growing med tech sector does not. MedTech Business Review is designed to redress that critical imbalance and put med tech firmly on the agenda where it belongs.



To book online please visit our website
www.medtechinvesting.com



INTRODUCTION

In 2007 the successful MedTech Investing (MTI) Europe conference series will enter its fourth year of fulfilling its principal aim – bringing together investors and innovators in an exclusive and focused educational and networking environment.

This year's MTI conference will build upon the successes of our past conferences to offer an even more focused programme, more formalised networking opportunities and a greater array of innovative med tech company investment opportunities.

The MTI Europe series is also pleased to announce a new partnership with the Ecole Polytechnique Fédérale de Lausanne (EPFL). Along with our existing partner, Imperial College London, we have now assembled a team unrivalled in market-led med tech research and innovation. Both Imperial and EPFL are members of our programme advisory committee and are central to the development of the conference.

KEY THEMES AND SUBJECTS ADDRESSED AT THE CONFERENCE WILL INCLUDE:

- **Navigating the journey from lab to patient: perspectives from the USA**
Professor Joachim Kohn, a world renowned expert in biomaterials medical research, will offer his views on the commercialisation of technology. He will draw upon his own experience in spinning out two start-ups and developing four licence agreements from his own laboratory.
- **CEO roundtable: 'Taking the temperature of the med tech industry'**
A panel of med tech CEOs from some of the leading companies in Europe will discuss the current state of the industry and how they intend to tackle future challenges and take advantage of the myriad of opportunities.
- **'Technology in focus' roundtable sessions**
Panels consisting of expert speakers will analyse the two sub sector areas of interventional cardiology and life sciences imaging. Areas explored will include technological development and innovation, reimbursement and regulatory environments and the general market conditions.

KEY BENEFITS OF ATTENDING

- Direct access to cutting-edge medical technology innovation potentially leading to some first-rate investment opportunities
- Direct access to the latest market intelligence from leading industry figures to inform your investment decisions in med tech
- Set up private one-to-one meetings for investor/med tech company dialogue
- Share experiences and analysis of the market with like-minded investors in a valuable networking environment
- Participate in the leading European conference specifically designed for investors and strategic partners.

Conference Format

The MedTech Investing Europe conference series uses an ideal mixture of med tech company presentations to investors, organised one-to-one meetings and focused plenary sessions spotlighting technology areas and other issues affecting the industry.

PLENARY SESSIONS

Industry experts drawn from the investment, corporate and academic worlds will present expert analysis and case studies. Campden adopt a roundtable discussion format in many sessions to encourage attendees and speakers to share experiences and views in a genuinely interactive environment.

MED TECH COMPANY PRESENTATIONS

Med tech company presentations give investors access to cutting edge, innovative med tech investment opportunities. Each presenting company will provide detailed information outlining the application of their technology and the opportunities it presents for investors and strategic partners. For a full list of med tech presenting companies confirmed to date, please visit www.medtechinvesting.com

ONE-TO-ONE MEETINGS

Following feedback from delegates at previous conferences, we have increased the amount of allocated time in the programme dedicated to one-to-one meetings between investors and med tech companies. Campden will facilitate the organisation of these meetings, allowing attendees to pre-book prior to the conference.

To book online please visit our website www.medtechinvesting.com

CONFERENCE PROGRAMME

THURSDAY 15TH FEBRUARY 2007

Chairman – day one

PROFESSOR PHILIPPE RENAUD

Director of the EPFL Centre of MicroNanoTechnology, Switzerland

08:15 REGISTRATION, REFRESHMENTS AND EXHIBITION

09:00 INTRODUCTION

CHAIRMAN'S OPENING REMARKS

PROFESSOR PHILIPPE RENAUD

Director of the EPFL Centre of MicroNanoTechnology, Switzerland

BioAlps welcome

PHILIPPE SORDET

President of BioAlps & Head of Economic Affairs, State of Vaud, Switzerland

09:10 KEYNOTE ADDRESS:

Navigating the journey from lab to patient: perspectives from the USA

PROFESSOR JOACHIM KOHN

Board of Governors Professor of Chemistry and Chemical Biology, Rutgers University, USA

The dynamics driving the success of the Swiss med tech industry

PROFESSOR DR GILBERTO BESTETTI

Head of CTI Medtech, the Innovation Promotion Agency, Switzerland

10:00 AN UPDATE ON PUBLIC MED TECH STOCK TRENDS

DR YVONNE GUNSCH WEGMANN

Vice President SWX Swiss Exchange, Switzerland

10:20 REFRESHMENTS, EXHIBITION AND NETWORKING

11:00

INVESTOR OPPORTUNITIES MED TECH COMPANY PRESENTATIONS

Med tech companies to present innovative technology and investment opportunities to an audience of investors

12:15 LUNCH

13:00

MED TECH INVESTORS AND INNOVATORS ONE-TO-ONE MEETINGS

Med tech companies and investors can meet and network in pre-arranged one-to-one meetings

13:30

INVESTOR OPPORTUNITIES MED TECH COMPANY PRESENTATIONS

Med tech companies to present innovative technology and investment opportunities to an audience of investors

15:00 REFRESHMENTS, EXHIBITION AND NETWORKING

15:30

MED TECH INVESTORS AND INNOVATORS ONE-TO-ONE MEETINGS

Med tech companies and investors can meet and network in pre-arranged one-to-one meetings

16:15 TECHNOLOGY IN FOCUS ROUNDTABLE:
INTERVENTIONAL CARDIOLOGY

A panel of leading experts drawn from the academic, corporate and investment world will analyse this technology area to give an in-depth, analytical view of interventional cardiology.

Areas discussed will include:

- Examining environmental factors driving growth
- The value of the sub sector and technology area
- Innovation – looking ahead to future technological development
- Exploring the reimbursement and regulatory environments

PROFESSOR PHILIPPE RENAUD

Director of the EPFL Centre of MicroNanoTechnology, Switzerland

PROFESSOR ULRICH SIGWART

Pioneer of interventional cardiology

MARIE JOSÉ PLIQUE

General Manager, MedC Partners, Switzerland

17:45 CLOSING COMMENTS

Medical technologies in the BioAlps region, the Lake Geneva Biotech & Medtech Cluster

DR BENOIT DUBUIS

Head of Life Sciences, EPFL, Switzerland

CHAIRMAN'S CLOSING REMARKS

PROFESSOR PHILIPPE RENAUD

Director of the EPFL Centre of MicroNanoTechnology, Switzerland

18:00 CONFERENCE CLOSE AND COACHES DEPART FOR
DRINKS RECEPTION AT MUSÉE OLYMPIQUE, LAUSANNE

20:00 COACHES WILL RETURN PARTICIPANTS TO
CENTRAL LAUSANNE

FRIDAY 16TH FEBRUARY 2007

Chairman – day two

PROFESSOR JEFF HUBBELL

Head of the Laboratory for Regenerative Medicine & Pharmaco-biology, EPFL, Switzerland

08:15 REGISTRATION, REFRESHMENTS AND EXHIBITION

08:30

MED TECH INVESTORS AND INNOVATORS ONE-TO-ONE MEETINGS

Med tech companies and investors can meet and network in pre-arranged one-to-one meetings

09:00 INTRODUCTION

CHAIRMAN'S OPENING REMARKS

PROFESSOR JEFF HUBBELL

Head of the Laboratory for Regenerative Medicine & Pharmaco-biology, EPFL, Switzerland

09:00 TECHNOLOGY IN FOCUS ROUNDTABLE:
IMAGING IN LIFE SCIENCES

As with the first day's roundtable session, we have convened a group of industry experts to analyse the imaging technology

SPEAKER PROFILES

area and market. Leading experts from the academic and corporate world will cover areas including:

- Examining environmental factors driving growth
- The value of the sub sector and technology area
- Innovation – looking ahead to future technological development
- Exploring the reimbursement and regulatory environments

PROFESSOR PIERRE MAGISTRETTI

Co-director of the Brain Mind Institute, EPFL, Switzerland

PROFESSOR JEFF HUBBELL

Head of the Laboratory for Regenerative Medicine & Pharmaco-biology, EPFL, Switzerland

PROFESSOR RICHARD FRACKOWIAK

University College London, UK

HANS MICHELS

Executive Director, ABN Amro, The Netherlands

PROFESSOR RIFAT ATUN

Director of the Centre for Health Management, Imperial College London, UK

10:30 REFRESHMENTS, EXHIBITION AND NETWORKING

11:00

INVESTOR OPPORTUNITIES MED TECH COMPANY PRESENTATIONS

Med tech companies to present innovative technology and investment opportunities to an audience of investors

12:15 LUNCH

13:15

MED TECH INVESTORS AND INNOVATORS ONE-TO-ONE MEETINGS

Med tech companies and investors can meet and network in pre-arranged one-to-one meetings

13:45

INVESTOR OPPORTUNITIES MED TECH COMPANY PRESENTATIONS

Med tech companies to present innovative technology and investment opportunities to an audience of investors

14:45

MTBR CEO ROUNDTABLE: TAKING THE TEMPERATURE OF THE MED TECH INDUSTRY

CEOs from some of the leading med tech corporates will discuss overarching trends and what this means for the future direction of the industry. How can the industry best tackle future challenges and take advantage of the myriad of opportunities?

MALCOLM CARLISLE

Managing Director, Eschmann Holdings, UK

DRAGO CERCHIARI

CEO, Sorin Group, Italy

SRINI SESHADRI

Group Managing Director, Smiths Medical, UK

DR FREDERIC NEFTEL

President & CEO, Debiotech SA, Switzerland

16:30

CHAIRMAN'S CLOSING REMARKS

PROFESSOR JEFF HUBBELL

Head of the Laboratory for Regenerative Medicine & Pharmaco-biology, EPFL, Switzerland

16:40

COACHES DEPART FOR CENTRAL LAUSANNE



Professor Rifat Atun is the director of the Centre for Health Management at the Business School, Imperial College London, where he leads a multidisciplinary research group exploring the adoption and diffusion of complex innovations and technologies in health systems. He is also director of Molecular Vision and Visbion (two imaging and diagnostics companies) and Medixine Oy (a information and communications healthcare software company).



Professor Gilberto Bestetti is chairman of the board and partner at Novo Business Consultants. He has extensive experience of the interface between strategy and implementation in the fields of management of innovation, change management, risk management and process analysis and reengineering.



Malcolm Carlisle is the group managing director of Eschmann Holdings Ltd. He has nearly 40 years experience in the industry having held positions at companies including ICI Pharmaceuticals, Colgate Palmolive and Smiths Group Medical Systems.



Drago Cerchiari, Ph.D., is the chief executive officer of SORIN GROUP – a position he has held since 2003. SORIN is a global firm with almost \$1 billion revenues and 4500 employees in 80 countries. It is the largest European cardiovascular medical device company. Mr Cerchiari is also chairman of Eucomed, the European association for the medical technology industry.



Dr Benoit Dubuis established the School of Life Sciences at EPFL and served as its first dean. He also founded the BioAlps organisation and co-founded Eclison, the first Swiss life sciences seed-fund and incubator. Dr Dubuis has 15 year of international experience in life sciences – both in industry and academic science management.



Professor Richard Frackowiak is a professor of cognitive neurology at UCL and director of the Department of Cognitive Studies at the Ecole Normale Supérieure in Paris. He founded and chaired the Wellcome Department of Imaging Neuroscience and its Functional Imaging Laboratory in 1994, where he continues to be research active as a principal investigator with a Wellcome Trust programme grant.



Jeffrey Alan Hubbell is professor and director of the Integrative Biosciences Institute and professor of the Institute for Chemical Sciences and Engineering at EPFL. His research is focussed in the field of biomaterials with applications in tissue engineering and drug delivery.



Professor Joachim Kohn is on the board of governors professor of chemistry and chemical biology at Rutgers University and an adjunct associate professor of orthopaedics at the New Jersey Medical School. His research focuses on the development of new biomaterials and he has pioneered the use of combinatorial and computational methods for the optimisation of biomaterials for specific medical applications.



Hans Michels has been the head of medical services and devices sector for ABN AMRO since November 2001. During that period he has advised numerous clients on corporate transactions in the healthcare sector, both strategic players and financial investors.



Professor Philippe Renaud is director of the EPFL Centre of MicroNanoTechnology, a large clean room facility. His research interests are directed towards BioMEMS technologies and applications. Professor Renaud's main fields of expertise are in microfluidics and cell-chips applications.



Marie José Plique is the general manager of MedC Partners, an integrated regulatory and marketing consultancy. She has accumulated 20 years of experience in the Medical Device industry, with a combination of scientific, operational and business management expertise. Most recently, Ms Plique was business unit director of GYNECARE, a Johnson & Johnson Company, specialised in women healthcare in the gynaecological and urological fields.



Srini Seshadri was appointed group managing director of Smiths Medical in March 2006. He joined Smiths from GE Healthcare Technologies where he had been chief marketing officer since 2004. Srini served more than 20 years at GE in two different businesses, GE Plastics and GE Healthcare. He has worked in and run global businesses from the USA, Paris and London.



Philippe Sordet is the director of economic affairs for the State of Vaud. He is in charge of management for economic promotion and regional development. He is also the president of BioAlps, the Lake Geneva Biotach & Medtech Cluster.



Dr Yvonne Gunsch-Wegmann is responsible for issuer and investor relations for both the SWX Swiss Exchange and virt-x, the pan-European stock exchange in London. She holds a PhD in medicine and has several years of clinical and scientific experience.

PLEASE COMPLETE IN BLOCK CAPITALS

Please register me _____ place(s) to attend MedTech Investing Europe 2007 at a cost of:

- £595.00 per person (discount valid until 15th December 2006)
 €895.00 per person (discount valid until 15th December 2006)
 £795.00 per person (full rate from 16th December 2006)
 €1149.00 per person (full rate from 16th December 2006)

REGISTRATIONS CAN ONLY BE CONFIRMED ON RECEIPT OF PAYMENT

Title Forename

Surname

Organisation

Position

Address

.....

.....

.....

Postcode

Country

Telephone

Facsimile

Email

I have read and agree to the terms and conditions opposite.

.....

Bookings cannot be accepted without a signature.

Hotel Accommodation

Bedrooms have been reserved at a preferential price at a number of hotels in Lausanne for delegates attending this event. Prices vary according to the hotel. For further information and to make a booking please contact **Paul Girdler**, Absolute Corporate Events Ltd tel: **+44 (0) 1225 744666** fax: **+44 (0) 1225 744777** email: **paul@absolutecorporateevents.com** – quoting reference **MTI07**

Method of payment

Please charge my credit card:

Visa/Mastercard/Amex

Card number Expiry date

Name on card

Signature Date

I have paid by direct bank transfer. Bank transfers should carry the reference 'MTI07', the delegate's name and should be sent to:

HSBC, 54 Clarence Street, Kingston Upon Thames, KT1 1NP

Account name: **Campden Publishing Limited**

£ Account number: **81756486** Sort code: **40-26-12**

€ Account number: **59941382** Sort code: **40-05-15**

I enclose a cheque for £ made payable to **Campden Publishing Limited**

Are you a:

- institutional investor
 corporate investor / strategic partner
 investment fund manager
 family office / private investment company
 private investor
 other (please specify)
.....

How did you hear about this meeting?

.....
.....
.....
.....

BOOKING RETURN DETAILS

Return completed forms by fax to:

+44(0)20 7214 0512

or post to:

MedTech Investing Europe 2007,
Campden Publishing Ltd,
1 St John's Square,
London, EC1M 4PN,
United Kingdom

Registrations may also
be made by email to:
conferences@campden.com

Alternatively, telephone:

+44(0)20 7214 0544

Copies of this programme and
registration form can also be accessed
via our website:

www.medtechinvesting.com

TERMS & CONDITIONS

PROGRAMME ALTERATIONS

It may be necessary for reasons beyond the control of the organisers to alter the content and timings of the programme or the identity of the speakers.

CANCELLATIONS AND REGISTRATION POLICY

Cancellations must be received in writing by 15th January, 2007. No refunds can be made for cancellations received after this date. Registrations may be transferred to another delegate. The organisers reserve the right to refuse registration of admittance to the event. If admittance is refused, a full refund will be made.

CANCELLATION OF THE EVENT

In the unlikely scenario of the event being cancelled, either through force majeure or for any other reason, the liability of Campden Publishing Limited will be limited to the full return of the registration fee. No other claims against Campden Publishing Ltd will be considered.

DATA PROTECTION ACT

The information you provide will be held on our database. It will not be released to third parties unconnected with the Conference without your express permission.

DISCLAIMER

Please note that Campden Publishing Limited, the Organisers, do not endorse or recommend in any way any of the companies, individuals or firms presenting at, attending or associated with the conference nor the information given by them. All information provided at the Conference is for information only and to be used on an 'as is, with all faults' basis. The Organisers rely on the companies, individuals or firms presenting at or associated with the conference to present accurate and reliable information, however the Organisers give no warranty for it. The Organisers shall not be liable for any decision made or action taken by delegates based upon any information obtained at or as a result of attending the conference. Delegates are strongly advised to take appropriate professional advice before making any investment or entering into any agreement following attending the conference.